Left Ventricular Assist Device

Patients implanted with a left ventricular assist device as destination therapy and those with a prior history of gastrointestinal bleeding were at significantly higher risk for hospitalization due to recurrent bleeding, researchers noted.

A recall of Medtronic’s Heartware ventricular assist device batteries has been designated as class I — the most serious type.

The FDA has designated Medtronic’s recall of its ventricular assist device batteries due to electrical faults causing battery failure as class I, the most serious type.

Ancora Heart Inc. announced that the FDA granted breakthrough device designation to its transcatheter left ventricular implant to improve LV structure and function in patients with HF with reduced ejection fraction.

The FDA issued an alert to health care providers of a welding defect in the internal pump of Medtronic’s ventricular assist device that may cause pump thrombosis and pump malfunction.

Machine learning models to predict myocardial recovery among patients who underwent left ventricular assist device implantation outperformed prior regression-based prognostic models, according to new data in Circulation: Heart Failure.

For patients on left ventricular assist device support, the development of right HF at 3 months postimplantation increased the risk for repeated hospitalization and major adverse events, researchers reported.

Compared with white patients, Black patients who received a left ventricular assist device experienced a higher morbidity burden and smaller gains in functional capacity and quality of life, according to new MOMENTUM 3 trial data.

The FDA and Medtronic alerted health care providers to no longer implant patients with end-stage HF with a ventricular assist device system due to the frequency of neurological adverse events and mortality.

Abbott announced the FDA approved updated labeling for its implantable heart pump for use in pediatric patients with advanced refractory left ventricular HF.